Barry E. Greene's most recent trade in Sage Therapeutics Inc was a trade of 174,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Jul 2025 | 174,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Jul 2025 | 53,229 | 0 (0%) | 0% | - | Common Stock | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | 31 Jul 2025 | 46,940 | 0 (0%) | 0% | - | Common Stock | ||
| Karyopharm Therapeutics Inc | Barry E. Greene | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 4,600 | 4,600 | - | - | Nonstatutory Stock Option (right to buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2025 | 19,964 | 105,031 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.91 per share. | 10 Apr 2025 | 4,862 | 100,169 (0%) | 0% | 6.9 | 33,596 | Common Stock |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2025 | 174,000 | 174,000 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2024 | 50,400 | 97,340 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.96 per share. | 05 Aug 2024 | 12,273 | 85,067 (0%) | 0% | 9.0 | 109,966 | Common Stock |
| Karyopharm Therapeutics Inc | Barry E. Greene | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 69,000 | 69,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 168,000 | 168,000 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Aug 2023 | 195,000 | 195,000 | - | - | Stock Option (Right to Buy) | |
| Karyopharm Therapeutics Inc | Barry E. Greene | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 34,000 | 34,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 66,500 | 66,500 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 34.48 per share. | 10 Nov 2022 | 14,500 | 46,940 (0%) | 0% | 34.5 | 500,022 | Common Stock |
| Karyopharm Therapeutics Inc | Barry E. Greene | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2022 | 7,576 | 0 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Barry E. Greene | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.48 per share. | 11 Aug 2022 | 7,576 | 13,606 (0%) | 0% | 1.5 | 11,250 | Common Stock |
| Karyopharm Therapeutics Inc | Barry E. Greene | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 23,900 | 23,900 | - | - | Nonstatutory Stock Option (right to buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 69,920 | 69,920 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 43.15 per share. | 05 Aug 2021 | 23,640 | 32,440 (0%) | 0% | 43.1 | 1,020,054 | Common Stock |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 56.32 per share. | 16 Jun 2021 | 8,800 | 8,800 (0%) | 0% | 56.3 | 495,627 | Common Stock |
| Acorda Therapeutics Inc | Barry E. Greene | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 10,000 | 10,000 | - | - | Non-Employee Stock Option | |
| Karyopharm Therapeutics Inc | Barry E. Greene | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 23,900 | 23,900 | - | - | Nonstatutory Stock Option (right to buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 390,000 | 390,000 | - | - | Stock Options (Right to buy) |